The impact of a reimbursement rate reduction on the utilization of antiulcer, antidepressants and antidiabetics in Portugal: A time series analysis

References

• Chang AY, et al. Global burden of disease health financing collaborator network. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995-2050. Lancet. 2019 Jun 1;393(10187):2233–2260. DOI:10.1016/S0140-6736(19)30841-4.
   PubMed Web of Science ®Google Scholar
• García-Goñi M. Rationalizing pharmaceutical spending. IMF Working Papers 2022/190. Washington: International Monetary Fund; 2022.
   Google Scholar
• Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet. 2017;389:403–476. DOI:10.1016/S0140-6736(16)31599-9.
   PubMed Web of Science ®Google Scholar
• García-Gómez P, Mora T, Puig-Junoy J. Does €1 Per prescription make a difference? Impact of a capped low-intensity pharmaceutical co-payment. Appl Health Econ Health Policy. 2018;16:407–414.
   PubMed Web of Science ®Google Scholar
• Komagamine J, Hagane K. Effect of total exemption from medical service co-payments on potentially inappropriate medication use among elderly ambulatory patients in a single center in Japan: a retrospective cross-sectional study. BMC Res Notes. 2018;11:199.
   PubMedGoogle Scholar
• Kolasa K, Kowalczyk M. Does cost sharing do more harm or more good? A systematic literature review. BMC Public Health. 2016;16:992.
   PubMed Web of Science ®Google Scholar
• Austvoll-Dahlgren A, Aaserud M, Vist G, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008 Jan 23;1:CD007017. DOI:10.1002/14651858.CD007017. Update in: Cochrane Database Syst Rev. 2015;5:CD007017. PMID: 18254125.
   Google Scholar
• World Health Organization. Out-of-pocket payments, user fees and catastrophic expenditure. WHO; 2016. [cited Jan 2022]. Available from: http://www.who.int/health_financing/topics/financial-protection/out-of-pocket-payments/en/.
   Google Scholar
• Luiza VL, Chaves LA, Silva RM, et al. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database Syst Rev. 2015;2015:CD007017.
   PubMedGoogle Scholar
• INFARMED. Legislação farmacêutica compilada. [cited July 2021] Available from: https://www.infarmed.pt/web/infarmed/legislacao-farmaceutica-compilada.
   Google Scholar
• Diário da República Electrónico. [cited July 2021] Available from: https://dre.pt/.
   Google Scholar
• Liu SZ, Romeis JC. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly. Med Care. 2003;41:1331–1342.
   PubMed Web of Science ®Google Scholar
• Gemmill MC, Thomson S, Mossialos E. What impact do prescription drug charges have on efficiency and equity? evidence from high-income countries. Int J Equity Health. 2008;7:12.
   PubMed Web of Science ®Google Scholar
• IMS Health. Dados nacionais dataview IFP. Lisboa: IMS Health Portugal; 2005.
   Google Scholar
• IMS Health. Dados nacionais dataview IFP. Lisboa: IMS Health Portugal; 2012.
   Google Scholar
• IMS Health. Dados nacionais dataview IFP. Lisboa: IMS Health Portugal; 2015.
   Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. Use of ATC/DDD – WHOCC. [cited Nov 2021] Available from: https://www.whocc.no/use_of_atc_ddd/.
   Google Scholar
• Wagner AK, Soumerai SB, Zhang F, et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299–309.
   PubMed Web of Science ®Google Scholar
• Sinnott SJ, Normand C, Byrne S, et al. Copayments for prescription medicines on a public health insurance scheme in Ireland. Pharmacoepidemiol Drug Saf. 2016;25:695–704.
   PubMed Web of Science ®Google Scholar
• Damiani G, Federico B, Anselmi A, et al. The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis. BMC Health Serv Res. 2014;14:6.
   PubMed Web of Science ®Google Scholar
• Gokhale M, Dusetzina SB, Pate V, et al. Decreased antihyperglycemic drug use driven by high out-of-pocket costs despite medicare coverage gap closure. Diabetes Care. 2020;43:2121–2127.
   PubMed Web of Science ®Google Scholar
• Psenkova M, Foltán V, Mackovicova S, et al. PCV154. Impact of drug policy regulations on the consumption of antihypertensive drugs in Slovakia. Value Health. 2014;17:A499.
   PubMed Web of Science ®Google Scholar
• Rättö H, Aaltonen K. The effect of pharmaceutical co-payment increase on the use of social assistance – a natural experiment study. PLoS One. 2021;16:e0250305.
   PubMed Web of Science ®Google Scholar
• Rättö H, Kurko T, Martikainen JE, et al. The impact of a co-payment increase on the consumption of type 2 antidiabetics – a nationwide interrupted time series analysis. Health Policy. 2021;125:1166–1172.
   PubMed Web of Science ®Google Scholar
• Kolasa K, Kowalczyk M. The effects of payments for pharmaceuticals: a systematic literature review. Health Econ Policy Law. 2019;14:337–354.
   PubMed Web of Science ®Google Scholar
• Andersson K, Petzold MG, Sonesson C, et al. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy. 2006;79:231–243.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11:730–740.
   PubMed Web of Science ®Google Scholar
• Hernández-Izquierdo C, González López-Valcárcel B, Morris S, et al. The effect of a change in co-payment on prescription drug demand in a national health system: The case of 15 drug families by price elasticity of demand. PLoS One. 2019;14:e0213403.
   PubMed Web of Science ®Google Scholar
• Laba TL, Cheng L, Worthington HC, et al. What happens to drug use and expenditure when cost sharing is completely removed? Evidence from a Canadian provincial public drug plan. Health Policy. 2020;124:977–983.
   PubMed Web of Science ®Google Scholar
• Varley A, Cullinan J. Are payment methods for prescription drugs associated with polypharmacy in older adults in Ireland? Evidence from the TILDA cohort study. BMJ Open. 2020;10:e036591.
   PubMed Web of Science ®Google Scholar
• Kočiš Krůtilová V, Bahnsen L, De Graeve D. The out-of-pocket burden of chronic diseases: the cases of Belgian, Czech and German older adults. BMC Health Serv Res. 2021;21:239.
   PubMed Web of Science ®Google Scholar
• Beckman L, von Kobyletzki L, Svensson M. Economic costs of antidepressant use: a population-based study in Sweden. J Ment Health Policy Econ. 2019;22:125–130.
   PubMed Web of Science ®Google Scholar
• HMR Health Market Research. National market watch. Lisbon: HMR Portugal; 2011.
   Google Scholar
• Stadhouders N, Koolman X, Tanke M, et al. Policy options to contain healthcare costs: a review and classification. Health Policy. 2016;120:486–494.
   PubMed Web of Science ®Google Scholar
• Heo JH, Rascati KL, Lee EK. Prediction of change in prescription ingredient costs and co-payment rates under a reference pricing system in South Korea. Value Health Reg Issues. 2017;12:7–19.
   PubMedGoogle Scholar
• INFARMED. [cited Nov 2021]. Available from: https://www.infarmed.pt/web/infarmed/entidades/medicamentos-uso-humano/monitorizacao-mercado/relatorios.
   Google Scholar
• INFARMED. [cited Nov 2021]. Available from: https://www.infarmed.pt/web/infarmed/entidades/medicamentos-uso-humano/monitorizacao-mercado/estatistica-anual/relatorios-anuais.
   Google Scholar
• Joyce GF, Escarce JJ, Solomon D, et al. Cost sharing cuts employers’ drug spending – but employees don't get the savings. Santa Monica (CA): RAND Corporation; 2002; [cited Jan 2022]. Available from: https://www.rand.org/pubs/research_briefs/RB4553.html.
   Google Scholar
• Lenzi J, Gianino MM. Switch from public to private retail pharmaceutical expenditures: evidence from a time series analysis in Italy. BMJ Open. 2022;12:e055421.
   PubMed Web of Science ®Google Scholar
• Non M, van Kleef R, van der Galiën O, et al. The effect of reinsuring a deductible on pharmaceutical spending: a Dutch case study on low-income people. Health Policy. 2019;123:976–981.
   PubMed Web of Science ®Google Scholar
• Behera DK, Dash U. Examining the state level heterogeneity of public health expenditure in India: an empirical evidence from panel data. Int J Healthc Technol Manag. 2018;17(1):75–95.
   Web of Science ®Google Scholar
• Guets W, Behera DK. Does disability increase households’ health financial risk: evidence from the Uganda demographic and health survey. Glob Health Res Policy. 2022;7:2. DOI:10.1186/s41256-021-00235-x.
   PubMedGoogle Scholar
• Davoudi A, Ahmadi M, Sharifi A, et al. Studying the effect of taking statins before infection in the severity reduction of COVID-19 with machine learning. Biomed Res Int. 2021 Jun 19;2021:9995073. DOI:10.1155/2021/9995073.
   PubMed Web of Science ®Google Scholar